## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 1 of 2

Complete if Known		
Application Number	10/577,840	
Filing Date	February 1, 2007	
First Named Inventor	Pere Joan Cardona Iglesias	
Art Unit	1633	
Examiner Name	Fereydoun Ghotb Sajjadi	
Attorney Docket No.	TJA-139US	

Considered

		Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Examiner C Initials* N	Cite No.1	Number - Kind Code <sup>2 (If known)</sup>			
		US-2007/0269501 A1	11-22-2007	Cardona Iglesias et al.	
		US-			
		US-			1
		US-			

		FOREIGN PA	TENT DOCUMEN	TS		_
		ite Publication Date Applicant of Ci		Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Examiner Initials*	Cite No.1			Figures Appear	T	
		ES 2 231 037 (corresponds to U.S. 2007/0269501 A1)	05-01-2005	Archivel Technologies SL		
		WO 03/063897 A1	08-07-2003	Modi		
						L
						<b>!</b>
						누
					L	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

Examine

Signature

"Approximate undust crisions neegination number (optional)," See Bind Caded in USPTO Patent December 3 were multipleased in VIRPO Patent December 3 were multipleased on VIRPO Patent December 3 were subject to the patent of VIRPO Standard St.3).

\*For Japanese patent documents, the indication of the year of the regn of the Emperor must procede the serial number of the patent document. For all patents of the patent documents are subject to the decument under WIPO Standard ST.16 if possible.

\*Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the The collection of information is required by 37 CFA 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is operated by \$1.05.C. 12.07 and 37 CFA 1.14. This collection is estimated to lake 2 hours produced including spathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any commented in the amount of time you require to complete this form and/or suppression for rectuding this burden, should be sent to the their information Officer, U.S. Petent and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, Ve. 22313-1450. DOI SOI TREST OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Ve. 22313-1450. DOI SOI TREST OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Ve. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 2 of 2

Complete if Known			
Application Number	10/577,840		
Filing Date	February 1, 2007		
First Named Inventor	Pere Joan Cardona Iglesias		
Art Unit	1633		
Examiner Name	Fereydoun Ghotb Sajjadi		
Attorney Docket No.	TJA-139US		

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catabog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²	
	01	ORME, "Preclinical testing of new vaccines for tuberculosis: A comprehensive review", Science Direct, Vaccine Vol. 24 (2006) 2-19		
	02	LARSON ET AL., "Immunology - Resistance to Tuberculosis in Mice immunized with BCG disrupted in Oil", Immunology, Nature Publishing Group, Vol. 198, June 22, 1963, pages 1214-1215		
	03	CHUGH ET AL., "Protective Efficacy of Different Cell-Wall Fractions of Mycobacterium tuberculosis", Folia Microbiol. 37 (6), 407-412 (1992)		
	04	D.B. PAL AND SHRINIWAS, "Role of cellwall vaccine in prophylaxis of tuberculosis", Indian J Med Res 65, 3, March 1977, pp. 340-345		
	05	AGGER ET AL., "Specific Acquired Resistance in Mice Immunized with Killed Mycobacteria", Scand. J. Immunol. 56, 443-447, 2002		
	06	KAUFMANN, "Envisioning future strategies for vaccination against tuberculosis", Nature Reviews Immunology/AOP, published online August 18, 2006		
	m			
			TE	
	-		-	
	-		E	

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

\*EDAMHIRES. Initial if reference considence, whether or not citation is in conformance with NRPP 609. Draw line through citation in not in conformance with NRPP 609. Draw line through citation in not in conformance with NRPP 609. Draw line through citation in not in conformance with NRPP 609. Draw line through citation in not in conformance with NRPP 609. Draw line through a line in the line of the